On The Horizon

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

By Malecare|2016-04-28T16:08:19-04:00April 28th, 2016|Advanced Prostate Cancer, Clinical Trials & Research, Drugs & Treatments, On The Horizon, survival, Survival, Uncategorized|2 Comments

On The Horizon – Tests That Can Inform Us If A Drug Will Work Before We Take The Drug

We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]

By Malecare|2017-10-19T10:46:49-04:00November 12th, 2015|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Biomarkers and Prognostic Tools, CTCs, Drugs & Treatments, Enzalutamide (MDV-3100), On The Horizon, prognostic tools, Research, taxanes, Uncategorized, Xtandi, Zytiga|0 Comments

On The Horizon – Galetrone (TOK-001) for Men with Advanced Prostate Cancer

It is probably still years off, but it is worth watching. Galetrone (TOK-001) has just completed phase II trials with the results scheduled to be released at ASCO-GU at the end of the month. I will be attending this conference and will be present for their presentation and report it to you from the conference. [...]

By Malecare|2017-10-19T10:49:07-04:00January 10th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, TOK-001 (Galeterone)|2 Comments

On the Horizon – Targeting Bones in the Treatment of Advanced Prostate Cancer

Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]

By Malecare|2017-10-19T10:49:44-04:00June 21st, 2013|Advanced Prostate Cancer, Bone Metastases, cabozantinib, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC|0 Comments

An Alternative to Radiation for Pain Relief Of Painful Bone And Soft-Tissue Tumors – Microwave Ablation

Currently as our advanced prostate cancer progresses and we develop bone and soft tissue tumors our pain increases significantly. Current treatment options for the palliation of this pain includes painkillers (including opioids and methadone), radiation and in rare incidents surgery. All of these options have significant limitations. Drugs eventually become less effective, especially for breakout [...]

By Malecare|2017-10-19T10:50:01-04:00April 15th, 2013|adjuvant therapy, Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Pain, Research, Uncategorized, Understanding APC|0 Comments

On the Horizon- A Better ADT Treatment with Less Side Effects

GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013. The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a [...]

By Malecare|2017-10-19T10:50:02-04:00April 7th, 2013|Advanced Prostate Cancer, Capesaris, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, On The Horizon, Uncategorized|0 Comments

On the Horizon – CABOZANTINIB IN MEN WITH ADVANCED PROSTATE CANCER: RESULTS OF A PHASE II RANDOMIZED TRIAL

Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. It is designed to target the men with castration resistant prostate cancer (CRPC). Results from a phase II randomized discontinuation trial with an expansion cohort of XL184 have recently been released. The trial included men [...]

By Malecare|2017-10-19T10:50:15-04:00January 15th, 2013|Advanced Prostate Cancer, cabozantinib, Drugs & Treatments, LX184, On The Horizon, Uncategorized, Understanding APC|1 Comment

On the Horizon – Cabozantinib for the Treatment of Bone Mets in Men with Advanced Prostate Cancer

According to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan men with advanced prostate cancer experienced significant and rapid positive effects from an investigational treatment known as cabozantinib. In a n article published online in the Journal of Clinical Oncology (Nov. 19, 2012) approximately two-thirds of men who were treated with [...]

By Malecare|2020-02-04T10:20:31-05:00December 13th, 2012|Advanced Prostate Cancer, cabozantinib, Clinical Trials, Clinical Trials, Drugs & Treatments, Research, Uncategorized|0 Comments

A Weed Killer Drug From Mediterranean Kills Prostate Cancer Tumor Cells

Johns Hopkins Kimmel Cancer Center along with Danish researchers have announced the development of a novel, investigational anticancer drug (G202) that has been described as a molecular grenade that targets cancer cells. The drug is able to travel undetected by normal cells through the bloodstream until it is activated by a specific cancer proteins, then [...]

By Malecare|2012-07-10T09:20:23-04:00July 10th, 2012|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, General Information, On The Horizon, Research, Uncategorized|2 Comments

Combining MDV-3100 & Provenge – A Wave of the Future?

I have heard some occasional discussion that once (that is if) enzalutamide (MDV-3100) is approved by the FDA for the treatment of men with advanced prostate cancer, it will over shadow Provenge. On the contrary, I believe that the approval of enzalutamide will actually encourage additional use of Provenge resulting in the increasing use of [...]

By Malecare|2012-06-19T20:59:36-04:00June 19th, 2012|abiraterone acetate, Advanced Prostate Cancer, Combination Therapy, Drugs & Treatments, Enzalutamide (MDV-3100), General Information, MDV3100, On The Horizon, Provenge, Uncategorized, Understanding APC|10 Comments